ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Biotechnology	154.29M	74.15M	7.70M	5.69M	13.81M
Total	154.29M	74.15M	7.70M	5.69M	13.81M

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
United States of America	154.20M	74.01M	-	-
PRC	97.00K	139.00K	386.00K	538.00K
Total	154.29M	74.15M	386.00K	538.00K

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 27, 2026

Data Sources Report a data error